Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

@article{Kotlyar2015RiskOL,
  title={Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.},
  author={David S Kotlyar and James D Lewis and Laurent Beaugerie and Ann M Tierney and Colleen Brensinger and Javier P Gisbert and Edward Vincent Loftus and Laurent Peyrin-Biroulet and Wojciech C Blonski and Manuel van Domselaar and Maria Stella Chaparro and Sandipani Sandilya and Meenakshi Bewtra and Florian Beigel and Livia Biancone and Gary R. Lichtenstein},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2015},
  volume={13 5},
  pages={847-58.e4; quiz e48-50}
}
BACKGROUND & AIMS Thiopurine therapy for inflammatory bowel disease (IBD) has been associated with increased risk for lymphoma. We estimated the relative risk of lymphoma in patients with IBD exposed to thiopurines and compared relative risk values derived from population-based studies with those from referral center-based studies. We investigated whether active use increased risk compared with past use, and whether sex, age, or duration of use affects risk of lymphoma. METHODS We searched… CONTINUE READING